ESMO 2024: DESTINY-Breast12 Updates

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight change in findings from a retrospective trial of patients with breast cancer presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard chemotherapy in patients with advanced breast cancer.